Radio-223 y aumento de la supervivencia en cáncer de próstata metastásico resistente a la castración (CPRCM) ¿Cómo, cuando, y para qué? - page 16

ALSYMPCA

Variables secundarias de eficacia (I): SSE

Sator O. Et al. The Lancet Oncology. 2014;15(7):738-46

SEO Version

Warning.

You are currently viewing the SEO version of !text.
It has a number of design and functionality limitations.

We recommend viewing the Flash version or the basic HTML version of this publication.

1...,6,7,8,9,10,11,12,13,14,15 17,18,19,20,21,22,23,24,25,26,...37